CD274 and head and neck squamous cell carcinoma: The JAVELIN Head and Neck 10011 tested addition of the PD-L1 inhibitor avelumab (not validated in HNSCC) to chemoradiation (CRT) in locally advanced HNSCC, without PD-L1 biomarker selection.